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We investigated the association between plasma 25(OH)D and the subsequent colorectal cancer incidence risk by a nested case–
control study in The Japan Public Health Center-based Prospective Study, covering 375 newly diagnosed cases of colorectal cancer
from 38373 study subjects during a 11.5-year follow-up after blood collection. Two controls were matched per case on sex, age,
study area, date of blood draw, and fasting time. In a conditional logistic regression model with matched pairs adjusted for smoking,
alcohol consumption, body mass index, physical exercise, vitamin supplement use, and family history of colorectal cancer, plasma
25(OH)D was not significantly associated with colorectal cancer in men or in women. However, the lowest category of plasma
25(OH)D was associated with an elevated risk of rectal cancer in both men (odds ratio (OR), 4.6; 95% confidence interval (CI), 1.0–
20) and women (OR, 2.7, 95% CI, 0.94–7.6), compared with the combined category of the other quartiles. Our results suggest that a
low level of plasma 25(OH)D may increase the risk of rectal cancer.
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Ecologic studies have reported that sunlight or solar ultraviolet B
exposure is inversely associated with the risk of colorectal cancer
incidence and mortality in the United States (Grant and Garland,
2004; Giovannucci, 2005) and in Japan (Mizoue, 2004). This
ultraviolet B is involved in the production of vitamin D from
7-dehydrocholesterol in the skin (Holick, 2004). Vitamin D, which
is derived from skin and dietary products or supplemental sources,
is catalysed to 25-hydroxyvitamin D in the liver, which is the most
useful measure of vitamin D status (Hunter, 1998). The 25-
hydroxyvitamin D re-enters the circulation and is converted in the
kidney by 25-hydroxyvitamin D-1a-hydroxylate to 1,25-dihydroxy-
vitamin D, which regulates calcium metabolism through its
interaction with its major target tissues, bone and intestine;
25-hydroxyvitamin D is also metabolised in colorectal mucosa for
regulation of cellular growth.
Several prospective studies reported that 25-hydroxyvitamin D
in the blood was inversely associated with colorectal cancer risk
(Garland et al, 1989; Braun et al, 1995; Wactawski-Wende et al,
2006), and especially distal colon and rectal cancer (Tangrea et al,
1997; Feskanich et al, 2004). One cohort was used to analyse a
small number of cases (Garland et al, 1989; Braun et al, 1995),
while others were from specific populations such as Finnish male
smokers (Tangrea et al, 1997) and US nurses (Feskanich et al,
2004). Further confirmation is needed from general populations,
especially with a different sunlight exposure and skin pigmentation
reducing the cutaneous synthesis of vitamin D (Clemens et al,
1982; Matsuoka et al, 1991).
We investigated the association between plasma 25-hydroxy-
vitamin D and the subsequent risk of colorectal cancer in a
nested case–control study in a large general population cohort in
Japan.
MATERIALS AND METHODS
The Japan Public Health Centre-based Prospective Study (JPHC
study) is an ongoing cohort study investigating cancer, cardiovas-
cular disease, and other lifestyle-related diseases. The first group
(Cohort I) of the JPHC study started in 1990 and the second group
(Cohort II) in 1993 (Watanabe et al, 2001). Study subjects were
mainly residents living in several municipalities in each area
administered by a Public Health Center, aged 40–59 years for
Cohort I and 40–69 years for Cohort II. Two more subcohorts of
health check-up examinees and random samples from one city
aged 40–69 were added to Cohort II. The study subjects were
identified by the population registry in each municipality. We
studied a cohort of 65803 men and 67520 women. Our study was
approved by the institutional review board of the National Cancer
Centre, Tokyo, Japan.
Using a self-administered questionnaire, study subjects were
asked to provide information about their personal and familial
medical histories, smoking, alcohol consumption, frequency of
physical exercise, dietary habits, and other lifestyle factors. Their
dietary habits were assessed by a food-frequency questionnaire of
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II. A total of 50456 men (77%) and 55909 women (83%) filled out
and returned the questionnaire. Among the study subjects, 15258
men (23%) and 26703 women (40%) donated 10-ml of venous
blood, drawn into vacutainer tubes containing heparin, collected at
the time of their health check-ups (1990–1992 for Cohort I, and
1993–1995 for Cohort II), and divided into plasma and buffy
layers, and then preserved at  801C until analysis.
Follow-up
We followed study subjects until 31 December, 2003, obtaining
mortality details from the Ministry of Health, Labour and Welfare
as necessary. Subjects moving to other municipalities were
identified annually through residential registries in their Public
Health Center areas; 9.9% moved away, and 0.2% were lost to
follow-up.
Incidence data on colorectal cancer were collected for the JPHC
cancer registry through local major hospitals, and population-
based cancer registries. Indicators of the completeness of colo-
rectal cancer case ascertainment conformed to the international
standard (Parkin et al, 2002) as follows: 5.5% of incident cases
were notified by death certificates (Death Certificate Notification,
DCN); 2.2% did not have detailed information except death
certificates (Death Certificate Only, DCO); and 94.7% were verified
by histological examination (Histological Verification, HV). We
identified 375 cases (196 men and 179 women) of colorectal cancer
up to 31 December, 2003 from among the 38373 subjects (14004
men and 24369 women) who had returned the baseline
questionnaire, did not report diagnosis of any cancer, and
provided the blood samples. All 375 cases were pathologically
confirmed as adenocarcinoma, after excluding 18 cases of
unknown pathology and seven non-adenocarcinoma cases. Of
these, 256 subjects had cancer of the colon (International
Classification of Diseases for Oncology, Third edition (ICD-O-3)
(World Health Organisation, 2000) code C180–C189) and 119 had
cancer of the rectum (ICD-O-3 code C199 and C209). Colon
cancers were classified into proximal (ICD-O-3 code C180–C185)
or distal colon (ICD-O-3 code C186 and C187). Information on
tumour depth was available in 370 of the 375 cases, with 120
tumors of the intramucosal type corresponding to Tis in TNM
classification (International Union Against Cancer, 1997) and 250
of the invasive type corresponding to T1 or more.
For each case, two controls were selected, using incidence
density sampling (Clayton and Hills, 1993), matched on sex, age
(within 3 years), date of blood draw (within 3 months), time since
last meal (within 4h), and study location (each Public Health
Centre area) from subjects who had no history of colorectal cancer
when the case was diagnosed.
Plasma 25-hydroxyvitamin D concentrations were measured by
the competitive protein-binding assay of Haddad and Chyu (1971).
A modified method using Gc-globulin (Sigma-Aldrich Co., St
Louis, MO, USA) instead of a tissue extract was adopted. All
samples were assayed by one commercial laboratory (Mitsubishi
Kagaku Bio-Clinical Laboratories Inc., Tokyo, Japan). Samples
from matched sets were assayed together. All laboratory personnel
were blinded with respect to case or control status. The intra-assay
coefficient of variation from the quality control samples was 8.4%
(n¼9).
Statistical analysis
Adjusted means for cases and controls were calculated using least
square means in analysis of covariance by the PROC GLM
procedure in SAS software (version 9.1; SAS Institute Inc., Cary,
NC, USA). Percentages of baseline characteristics were unadjusted
crude values. We used the extensions of the Mantel–Haenszel
procedure (Mantel, 1963) with matched pairs for a comparison of
the baseline characteristics and plasma 25-hydroxyvitamin D
between cases and controls, using the PROC FREQ procedure with
CMH option. We tested the linear trend of covariates among
controls by quartiles of plasma 25-hydroxyvitamin D, also using
the extensions of the Mantel–Haenszel procedure (Mantel, 1963).
The odds ratios (OR) and 95% confidence intervals (CI) for plasma
25-hydroxyvitamin D divided into quartiles based on control
distribution were calculated by a conditional logistic regression
model adjusted for pack–years of smoking (continuous), alcohol
consumption (continuous), body mass index (continuous),
physical exercise (less than once a week, or once a week or more),
vitamin supplement use (any vitamin supplements, i.e., B-
vitamins, vitamin C, E, A, multivitamins, or other), and family
history of colorectal cancer as well as using matched pairs. The
linear trend of OR was tested using the logarithmic-transformed
median value of plasma 25-hydroxyvitamin D in the category,
since the plasma value was log-normally distributed. The
heterogeneity over quartiles of plasma 25-hydroxyvitamin D levels
was tested by the Wald w
2 statistic. P-values for the trend were two-
sided, with 0.05 as the significance level. We estimated the ORs for
colorectal cancer as a whole, and also colon and rectal cancers
separately with assessment of difference between these two cancers
using a test for heterogeneity (Greenland, 1998). To examine
whether the plasma 25-hydroxyvitamin D levels affected the risk of
colorectal cancer differently between periods of high (July to
November) and low (December to June) blood levels, we
conducted a seasonally stratified analysis of blood drawn.
Additionally, we tried to estimate the risk for hypovitaminosis D
(15ngml
 1 (37.5nmoll
 1)) (Nesby-O’Dell et al, 2002).
RESULTS
Colorectal cancer cases in men smoked more, consumed more
alcohol beverages, and had a higher body mass index than their
controls, but also consumed less dietary fiber than controls
(Table 1). Female cases consumed more diet–origin vitamin D
than their controls.
No potential confounding factors correlated with plasma 25-
hydroxyvitamin D among controls (Table 2). Female controls in
the lowest quartile of plasma 25-hydroxyvitamin D consumed
more alcoholic beverages than other quartiles. Food and nutrient
intakes were not associated with plasma 25-hydroxyvitamin D
except n-3 polyunsaturated fatty acid intake in women, which is
contained in fish, a major source of dietary vitamin D in the
Japanese population (Nakamura et al, 2002). Dietary vitamin D did
not correlate with plasma 25-hydroxyvitamin D in either men or
women.
Plasma 25-hydroxyvitamin D was lower in rectal cancer cases
than their controls (Table 3). Median plasma levels were
24.3ngml
 1 in men and 26.6ngml
 1 in their controls
(P¼0.0051); 20.6ngml
 1 in women and 22.6ngml
 1 in their
controls (P¼0.093). There was no difference between colon cancer
cases and their controls.
Plasma 25-hydroxyvitamin D was not associated with the risk of
colorectal cancer in men or women, although there was a
suggestion of an inverse relationship in men (Table 4), with ORs
(95% CI) of 0.76 (0.42–1.4) for the second, 0.76 (0.39–1.5) for the
third, and 0.73 (0.35–1.5) for the highest quartile, compared to the
lowest quartile (P for trend, 0.39). It appeared that only the lowest
quartile had a somewhat higher risk than other quartiles for rectal
cancer risk, although again the trend test was not significant. The
ORs were 1.0 for the lowest, 0.17 for the second, 0.25 for the third,
and 0.075 for the highest quartile for men (P for trend, 0.06); colon
cancer did not show a similar association. In women, a similar
association was observed for rectal cancer risk, with ORs of 0.26,
0.46, and 0.33 for the second, third and highest quartiles
respectively (P for trend, 0.17). Heterogeneity tests between colon
Plasma vitamin D and colorectal cancer risk
T Otani et al
447
British Journal of Cancer (2007) 97(3), 446–451 & 2007 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yand rectal cancer risk were borderline (P¼0.06 in men; 0.04 in
women), using estimates from the statistical model for the trend test.
In addition to the main results, we calculated the rectal cancer
risk of the lowest quartile compared with the combined category of
other quartiles in men and women. These ORs were 4.6 (95% CI,
1.0–20) in men and 2.7 (95% CI, 0.94–7.6) in women. The fact that
the low plasma levels were associated with rectal cancer risk did
not substantially change when the first 2-year cases were excluded,
although the OR in men was attenuated (OR, 2.2 (95% CI, 0.44–11)
in men; OR, 2.7 (95% CI, 0.92–7.8) in women). Further adjustment
for n-3 polyunsaturated fatty acid or fish intake did not change the
main results (data not shown).
We repeatedly examined the association after stratifying data by
the season of blood collection, that is, that with high plasma levels
(July to November) or low plasma levels (December to June), and
by study location (northern or southern Japan), but the results did
not substantially change. These further analyses could not be
applied to rectal cancer separately because the numbers were too
small; similarly the risk of hypovitaminosis D could not be
investigated because of the small numbers (six men cases and six
men controls; 10 women cases and 28 women controls).
Table 2 Association between plasma 25-hydroxyvitamin D and covariates among controls at baseline
Quartiles of plasma 25-hydroxyvitamin D
Men Women
Variables Lowest Second Third Highest P for trend Lowest Second Third Highest P for trend
Range, ngml
 1 (o22.9) (22.9–27.5) (27.6–32.0) (32.1+) (o18.7) (18.7–22.2) (22.3–26.9) (27.0+)
Median, ngml
 1 19.9 25.0 29.6 35.6 16.6 20.6 24.1 31.4
Age, mean 57.6 55.1 56.9 58.0 0.45 55.3 57.9 56.8 55.6 0.92
Smoking, mean
a 25.9 23.9 21.4 23.9 0.44 0.8 1.3 0.4 0.2 0.22
Alcohol consumption, mean
a 172 172 183 174 0.40 11.2 3.6 4.6 3.5 0.062
Body mass index, mean
a 23.5 23.1 23.3 23.1 0.53 23.5 23.4 23.7 23.8 0.34
Physical exercise, n 18 21 16 20 0.70 11 16 12 15 0.83
Vitamin supplement use, n 15 9 21 8 0.30 14 15 12 13 0.74
Family history of colorectal cancer, n 0 1 1 2 0.15 0 2 1 1 0.47
Dietary fibre intake, mean
b 7.53 8.56 8.39 7.64 0.84 7.13 7.60 7.62 7.80 0.96
Folate intake, mean
b 338 340 331 312 0.091 279 288 292 300 0.48
Calcium intake, mean
b 451 463 497 443 0.57 429 419 437 399 0.24
Vitamin D intake, mean
b 6.30 6.84 7.14 6.47 0.92 5.00 5.19 4.84 5.54 0.067
n-3 fatty-acid intake, mean
b 1.30 1.44 1.47 1.31 0.81 1.07 1.13 1.08 1.20 0.026
Red meat intake, mean
b 17.8 17.8 16.2 17.0 0.50 10.6 13.8 13.4 12.9 0.49
Fish intake, mean
b 59.5 63.9 66.2 58.9 0.70 42.2 44.0 39.1 48.4 0.087
aAdjusted for age.
bAdjusted for age, cohort, and energy intake.
Table 1 Baseline characteristics of cases and controls
Men Women
Characteristics Cases Controls P Cases Controls P
n 196 392 179 358
Age (years), mean 56.9 56.9 0.69 56.5 56.4 0.35
Smoking (pack–years), mean
a 27.5 23.8 0.020 0.458 0.657 0.54
Alcohol consumption (gweek
 1 ethanol), mean
a 236 175 o0.0010 9.63 5.70 0.37
Body mass index (kgm
 2), mean
a 23.8 23.2 0.027 23.5 23.6 0.68
Physical exercise, n (%)
b 49 (26) 75 (20) 0.12 33 (19) 54 (15) 0.28
Vitamin supplement use, n (%) 35 (20) 53 (15) 0.11 24 (15) 54 (17) 0.43
Family history of colorectal cancer, n (%) 5 (2.6) 4 (1.0) 0.16 4 (2.2) 4 (1.1) 0.32
Total energy intake (kcalday
 1), mean
c 2021 2064 0.34 1277 1265 0.67
Dietary fibre intake (gday
 1), mean
d 7.76 8.05 0.047 7.83 7.58 0.16
Folate intake (mgday
 1), mean
d 328 329 0.60 298 291 0.31
Calcium intake (mgday
 1), mean
d 441 463 0.15 452 423 0.074
Vitamin D intake (mgday
 1), mean
d 6.58 6.67 0.54 5.57 5.16 0.047
n-3 fatty-acid intake (mgd
 1), mean
d 1.32 1.38 0.28 1.19 1.13 0.060
Red meat intake (gd
 1), mean
d 17.0 17.2 0.70 13.8 12.7 0.17
Fish intake (gd
 1), mean
d 62.2 62.0 0.88 46.7 43.6 0.15
aAdjusted for age.
bNumber (percentage) of subjects doing physical exercise once a week or more.
cAdjusted for age and cohort.
dAdjusted for age, cohort, and energy intake.
Table 3 Plasma 25-hydvroxyvitamin D between cases and controls
Plasma 25-hydroxyvitamin D, (ngml
 1)
Cases Controls P
a
Men
Colorectal cancer, n 196 392
Median [interquartile range] 27.3 [22.2–32.8] 27.6 [22.9–32.1] 0.67
Colon cancer, n 141 282
Median [interquartile range] 28.3 [23.0–35.0] 28.0 [23.0–32.3] 0.25
Rectal cancer, n 55 110
Median [interquartile range] 24.3 [20.2–29.1] 26.6 [22.9–31.2] 0.0051
Women
Colorectal cancer, n 179 358
Median [interquartile range] 22.5 [18.5–27.1] 22.3 [18.7–27.0] 0.91
Colon cancer, n 115 230
Median [interquartile range] 23.3 [19.1–27.3] 22.0 [18.5–27.5] 0.25
Rectal cancer, n 64 128
Median [interquartile range] 20.6 [17.8–25.3] 22.6 [19.1–26.5] 0.093
aTested by extensions of Mantel–Haenszel procedure with matched pairs.
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Our results suggest that a low level of plasma 25-hydroxyvitamin D
is associated with rectal cancer risk in both men and women but
not colon cancer. A significant inverse association between
25-hydroxyvitamin D and colorectal cancer, especially of the distal
colon and rectum has been reported (Tangrea et al, 1997;
Feskanich et al, 2004; Wactawski-Wende et al, 2006), whereas
another prospective study showed no such association with colon
cancer risk (Braun et al, 1995).
Comparison of the ranges of 25-hydroxyvitamin D levels in the
above studies is relevant. A Finnish cohort (Tangrea et al, 1997)
covered the lower and narrower range, that is 9.8 or less to more
than 19.2ngml
 1, as did the Women’s Health Initiative Study, a
randomised, double-blind, placebo-controlled trial among US
women, from less than 12.4–23.4ngml
 1 or more (Wactawski-
Wende et al, 2006). A Nurses’ Health Study among US women
(Feskanich et al, 2004) covered a higher and wider range (14.9, the
median for the lowest category to 35.3ngml
 1, the median for the
highest category). On the other hand, the small Washington
County Study covered a higher and narrower range (less than
17.2–30.1ngml
 1 or more) (Braun et al, 1995).
Our study similarly showed no association between colon cancer
and 25-hydroxyvitamin D in the higher and narrower range, that is,
below 22.9–32.1ngml
 1 or more in men and below 18.7–
27.0ngml
 1 or more in women. However, an effect of a low level
of 25-hydroxyvitamin D was found for rectal cancer in our subjects.
In short, populations covering the lower range of 25-hydroxyvitamin
D may show a preventive effect against colorectal cancer even with a
narrower variation of 25-hydroxyvitamin D. The higher range
presumably shows the protective effect only if they have a sufficiently
wide variation of 25-hydroxyvitamin D. Differences in our findings
from the Washington County Study may be due to the different
characteristics of the colon and rectum.
Additionally, this inconsistency may reflect assay differences.
Some studies used radioimmunoassay with an iodine-125 labelled
tracer (Braun et al, 1995; Tangrea et al, 1997; Feskanich
et al, 2004); others used a chemiluminescent radioimmunoassay
(Wactawski-Wende et al, 2006) or competitive protein-binding
assay (our study). If assay methodology differs among labora-
tories, even the same samples may show different measurements
(Binkley et al, 2004).
Differences between colon and rectum may derive from 1,25-
dihydroxyvitamin D receptor (Vitamin D receptor, VDR) expres-
sion. VDR also has some differences in genetic polymorphisms by
ethnic group. BsmI B and short poly A alleles, for example, are
more prevalent in Caucasians than in Japanese (Tokita et al, 1996;
Ingles et al, 1997), and may be protective against colorectal cancer
(Slatter et al, 2001). Japanese may be more vulnerable to rectal
cancer due to the low prevalence of this protective VDR genotype.
The Women’s Health Initiative study reported that calcium plus
vitamin D supplementation did not decrease the subsequent risk of
colorectal cancer over a follow-up of 7 years (Wactawski-Wende
et al, 2006). However, the supplementation might influence only
the group with low plasma levels, colorectal cancer risk among the
group with the lowest level of plasma 25-hydroxyvitamin D being
slightly, though not significantly, decreased.
It is not surprising that bioavailable vitamin D status did not
correlate with dietary vitamin D intake. Holick (2004) indicated
that over 90% of the vitamin D requirement comes from casual
exposure to sunlight. Of course, blood levels of 25-hydroxyvitamin
D partly reflect dietary intake of vitamin D (Nakamura et al, 2000,
2002), although our results did not show a positive correlation
between dietary and plasma vitamin D levels, partly due to the low
validity of the food frequency questionnaire. Spearman’s correla-
tion coefficients between dietary records and estimates from the
food frequency questionnaire were 0.26 for men and 0.38 for
women in Cohort I; 0.32 for men and 0.28 for women in Cohort II,
Table 4 Odds ratios (OR) and 95% confidence intervals (CI) of colorectal cancer for plasma 25-hydroxyvitamin D
Quartiles of plasma 25-hydroxyvitamin D
Lowest Second Third Highest
P for
heterogeneity
P for
trend
Men
Range, ngml
 1 (o22.9) (22.9–27.5) (27.6–32.0) (32.1+)
Median, ngml
 1 19.9 25.0 29.6 35.6
Colorectal cancer, n
a 43/74 40/85 36/85 44/80
Unadjusted OR
b (95% CI) 1.0
c 0.81 (0.49–1.3) 0.64 (0.36–1.1) 0.91 (0.50–1.7) 0.37 0.53
Adjusted OR
d (95% CI) 1.0
c 0.76 (0.42–1.4) 0.76 (0.39–1.5) 0.73 (0.35–1.5) 0.78 0.39
Colon cancer, n
a 25/54 27/55 29/66 38/62
Unadjusted OR
b (95% CI) 1.0
c 1.0 (0.55–1.8) 0.89 (0.46–1.7) 1.5 (0.73–3.0) 0.41 0.37
Adjusted OR
d (95% CI) 1.0
c 0.98 (0.48–2.0) 1.0 (0.48–2.3) 1.2 (0.51–2.7) 0.97 0.70
Rectal cancer, n
a 18/20 13/30 7/19 6/18
Unadjusted OR
b (95% CI) 1.0
c 0.39 (0.15–1.0) 0.26 (0.084–0.82) 0.16 (0.036–0.69) 0.055 0.0066
Adjusted OR
d (95% CI) 1.0
c 0.17 (0.024–1.2) 0.25 (0.051–1.3) 0.075 (0.0057–0.99) 0.19 0.06
Women
Range, ngml
 1 (o18.7) (18.7–22.2) (22.3–26.9) (27.0+)
Median, ngml
 1 16.6 20.6 24.1 31.4
Colorectal cancer, n
a 41/77 34/73 44/71 41/76
Unadjusted OR
b (95% CI) 1.0
c 0.92 (0.54–1.6) 1.1 (0.61–1.8) 0.98 (0.51–1.9) 0.96 0.96
Adjusted OR
d (95% CI) 1.0
c 1.0 (0.55–1.9) 1.2 (0.65–2.3) 1.1 (0.50–2.3) 0.92 0.74
Colon cancer, n
a 21/53 27/48 27/41 31/53
Unadjusted OR
b (95% CI) 1.0
c 1.3 (0.68–2.5) 1.8 (0.88–3.6) 1.9 (0.83–4.3) 0.38 0.10
Adjusted OR
d (95% CI) 1.0
c 1.7 (0.78–3.6) 2.1 (0.90–4.7) 2.1 (0.78–5.6) 0.34 0.12
Rectal cancer, n
a 20/24 7/25 17/30 10/23
Unadjusted OR
b (95% CI) 1.0
c 0.39 (0.14–1.1) 0.39 (0.15–1.0) 0.28 (0.087–0.88) 0.14 0.04
Adjusted OR
d (95% CI) 1.0
c 0.26 (0.069–1.0) 0.46 (0.15–1.4) 0.33 (0.084–1.3) 0.22 0.17
aNumbers of cases/controls.
bORs estimated using matched pairs without any adjustment.
cReference category.
dORs estimated using matched pairs with adjustment for pack–
years of smoking (continuous), alcohol consumption (g/week ethanol, continuous), body mass index (continuous), physical exercise (less than once a week, or once a week or
more), vitamin supplement use, and family history of colorectal cancer.
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addition, skin pigmentation is one of the determinants of 25-
hydroxyvitamin D levels. Oriental people show lower cutaneous
synthesis of vitamin D than white people (Matsuoka et al, 1991). In
addition to sunlight, dietary intake, and skin pigmentation, season
of blood sampling and subjects’ body mass index may influence
blood levels (Giovannucci, 2005; Giovannucci et al, 2006). Thus,
25-hydroxyvitamin D measurement is more appropriate way to
assess entirely vitamin D status than dietary intake.
An active form of vitamin D, 1,25-dihydroxyvitamin D, was not
investigated in the present study, as its half-life in the circulation
(less than 4h) is shorter than that of 25-hydroxyvitamin D
(approximately 2 weeks) and normal levels are maintained even
with vitamin D deficiency and low 25-hydroxyvitamin D levels,
making it unsuitable for studies of colorectal cancer risk (Braun
et al, 1995; Tangrea et al, 1997; Feskanich et al, 2004; Holick, 2004).
Although blood samples were collected before cancer diagnosis,
measurement errors may exist because only one blood sample for
each subject was used to measure plasma 25-hydroxyvitamin D
concentrations, causing random misclassification to attenuate
statistical associations. Long-term storage is recommended only at
temperatures of less than  181C (Hunter, 1998) and our plasma
storage ( 801C) satisfied this condition. Furthermore, this plasma
biomarker has a seasonal variation, declining in winter and rising
in summer, reflecting sunlight exposure (Holick, 2004). In fact, our
study controls’ levels were slightly lower among blood samples
drawn in winter (mean values from November to March;
26.3ngdl
 1 for men and 22.8ngdl
 1 for women) than those
drawn at other times (mean values from April to October;
28.4ngdl
 1 for men and 23.5ngdl
 1 for women). To minimise
bias, we matched date of blood collection between cases and
controls (within 3 months), differing by less than 1 month among
63% of the case–control pairs, only by 1–2 months among 14% of
them, and by 2–3 months among 17%. The proportion of case–
control pairs where both were drawn at high-level seasons of
plasma 25-hydroxyvitamin D (April to October) was 72% of all
pairs, so difference in timing of blood draw would minimally
impact on risk estimates.
In conclusion, a low plasma 25-hydroxyvitamin D level may be
associated with a subsequent risk of rectal but not colon cancer.
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